News about Industrial talks

Lupin's Climate Targets Across All Emission Scopes Validated by SBTi

Global pharmaceutical major Lupin Limited has announced that its greenhouse gas emissions reduction targets have been officially validated by the Science Based Targets initiative. The validation covers Scope 1, Scope 2 and Scope 3 emissions, aligning Lupin’s climate strategy with the Paris Agreement goal of limiting global temperature rise to 1.5°C.

Industrial talks | 16/12/2025 | By Darshana

Indoco Receives USFDA EIR for Patalganga API Manufacturing Facility

Indoco has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration for its API manufacturing facility at Patalganga following an inspection conducted in the month of September.

Industrial talks | 15/12/2025 | By News Bureau

Jubilant Pharmova Appoints Daniel J. O'Connor as CEO of Jubilant Therapeutics

Jubilant Pharmova has announced the appointment of Daniel J. O’Connor as CEO of its proprietary novel drugs business, Jubilant Therapeutics Inc.

Industrial talks | 02/12/2025 | By Dineshwori

Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions

Tsingke Biotech showcased its accelerated protein and antibody production platform at PEGS Europe 2025, announcing capabilities to generate proteins in as little as three days and antibodies within seven—offering a boost to biopharma developers seeking faster drug discovery timelines.

Industrial talks | 20/11/2025 | By Dineshwori

Merus, Halozyme Partner to Develop Subcutaneous Petosemtamab

Under the agreement, Merus will pay Halozyme upfront and milestone-based payments, with Halozyme also eligible for low- to mid-single-digit royalties on future ENHANZE-enabled petosemtamab sales.

Industrial talks | 19/11/2025 | By Dineshwori

Health Minister Marks AMRIT Pharmacy's 10th Anniversary, Announces Nationwide Expansion

AMRIT pharmacies offer medicines at discounts of around 50 percent, benefiting more than 6.85 crore patients to date. Medicines valued at over INR 17,000 crore have been dispensed through the network, resulting in cumulative patient savings of approximately INR 8,400 crore, according to the data shared.

Industrial talks | 17/11/2025 | By Dineshwori

Pfizer Completes Acquisition of Metsera

Pfizer has finalised its acquisition of Metsera, adding a portfolio of differentiated, clinical-stage obesity therapies with the potential to redefine future treatment standards. The deal strengthens and reshapes Pfizer’s internal medicine portfolio, positioning the company to compete more aggressively in therapeutic areas, globally.

Industrial talks | 14/11/2025 | By Dineshwori

Biocon Clarifies Media Reports on Possible Biocon Biologics Merger

Biocon has issued a clarification regarding recent media reports suggesting that the company is considering a potential merger of its unlisted subsidiary, Biocon Biologics Ltd. (BBL), along with IPO and share swap options.

Industrial talks | 14/11/2025 | By Dineshwori |  165

US FDA Appoints Richard Pazdur as Director of CDER

Pazdur is a 26-year veteran of the FDA and the Founding Director of its Oncology Center of Excellence (CoE). A regulatory innovator, he developed an integrated approach for cross-centre coordination of oncology product review to expedite the development of novel cancer therapies.

Industrial talks | 13/11/2025 | By Dineshwori

Biocon Posts Robust Q2FY26 Results as Biosimilars and Generics Drive Double-Digit Growth

Biocon reported a robust financial performance for the second quarter of FY26, with total revenue rising 21 percent year-on-year (YoY) to INR 4,389 crore, compared to INR 3,623 crore in Q2 FY25.

Industrial talks | 12/11/2025 | By Dineshwori |  212